These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 2226604)
41. [Clinical study on the effects of chemotherapy as treatment of renal cell carcinoma]. Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):43-9. PubMed ID: 3379331 [No Abstract] [Full Text] [Related]
42. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma. Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729 [TBL] [Abstract][Full Text] [Related]
49. Interferon plus vinblastine in renal carcinoma patients who had failed on interferon alone. Merimsky O; Chaitchik S Eur J Cancer; 1990; 26(8):921. PubMed ID: 2145941 [No Abstract] [Full Text] [Related]
50. Treatment of recurrent or metastatic renal cell carcinoma. Shah RN; Ahmad T; Eisen TG Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334 [TBL] [Abstract][Full Text] [Related]
51. Combination therapy in kidney cancer: the next revolution? Buti S; Bersanelli M Lancet Oncol; 2015 Nov; 16(15):1441-1442. PubMed ID: 26482275 [No Abstract] [Full Text] [Related]
52. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Bukowski RM Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599 [TBL] [Abstract][Full Text] [Related]
53. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Geller JI; Dome JS Pediatr Blood Cancer; 2006 Apr; 46(4):527. PubMed ID: 16365852 [No Abstract] [Full Text] [Related]
54. Efficacy of UFT for the treatment of renal cell carcinoma. Masuda F; Mori Y; Nakada J Prog Clin Biol Res; 1989; 303():707-9. PubMed ID: 2506559 [No Abstract] [Full Text] [Related]
55. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Becker A; Eichelberg C; Sun M Cancer; 2014 Jan; 120(1):7-10. PubMed ID: 24347382 [No Abstract] [Full Text] [Related]
56. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Halabi S; Rini BI; Escudier B; Stadler WM; Small EJ Cancer; 2015 Jun; 121(11):1906. PubMed ID: 25677867 [No Abstract] [Full Text] [Related]
57. Chest discomfort in a patient with cancer. Rabener MJ; Howell C JAAPA; 2015 Jun; 28(6):43-4, 466. PubMed ID: 25989434 [TBL] [Abstract][Full Text] [Related]
58. [Intraarterial chemotherapy for metastatic renal cell carcinomas: combination with MDR-overcoming agents]. Kakehi Y; Yoshida O; Segawa T; Kanematsu A; Hiura M; Shichiri Y; Arai Y Hinyokika Kiyo; 1994 Oct; 40(10):925-9. PubMed ID: 7992710 [TBL] [Abstract][Full Text] [Related]
59. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200 [TBL] [Abstract][Full Text] [Related]
60. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled. Eisen T BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]